Literature DB >> 1324082

Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.

Y Masuo1, T Ohtaki, Y Masuda, M Tsuda, M Fujino.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is structurally similar to vasoactive intestinal polypeptide (VIP). We investigated the characteristics and topographical distribution of [125I]PACAP binding sites compared with those of [125I]VIP binding sites in the rat brain. Radiolabeled PACAP and VIP showed highly specific binding to sections at the level of the dorsal hippocampus. The specific binding of [125I]PACAP was 10 times higher than that of [125I]VIP in hippocampal sections. [125I]PACAP binding was scarcely displaced by unlabeled VIP, while [125I]VIP binding was effectively displaced by unlabeled PACAP. Therefore, PACAP binding sites may reflect both PACAP specific binding sites and VIP/PACAP binding sites. However, the amount of VIP/PACAP binding sites was negligibly low. Autoradiography revealed that [125I]PACAP binding sites were dense in the piriform cortex, diagonal band, accumbens nucleus, anterior part of the striatum, hippocampal formation, habenular nucleus, lateral hypothalamic area, superior colliculus and dorsal raphe nucleus. Moderate to high labeling was observed in the medial septal nucleus, olfactory tubercle, caudal part of the striatum, most parts of the thalamus, supraoptic and periventricular hypothalamic nuclei, central gray, substantia nigra pars compacta, locus coeruleus, pontine reticular nucleus and cerebellum. Distribution pattern was remarkably different from that of [125I]VIP binding sites in the hippocampal formation, lateral hypothalamic area, substantia nigra pars compacta, pontine reticular nucleus and cerebellum. The present results suggest that PACAP may have a physiological role in the regulation of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324082     DOI: 10.1016/0006-8993(92)90430-h

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

2.  PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglödi; Yousef Tizabi
Journal:  J Mol Neurosci       Date:  2013-04-28       Impact factor: 3.444

3.  Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).

Authors:  Seth D Norrholm; Mahasweta Das; Gábor Légrádi
Journal:  Regul Pept       Date:  2005-05-15

4.  PACAP Protects Against Ethanol and Nicotine Toxicity in SH-SY5Y Cells: Implications for Drinking-Smoking Co-morbidity.

Authors:  Sridharan Manavalan; Bruk Getachew; Kebreten F Manaye; Syed J Khundmiri; Antonei B Csoka; Raechel McKinley; Andrea Tamas; Dora Reglodi; Yousef Tizabi
Journal:  Neurotox Res       Date:  2017-03-24       Impact factor: 3.911

5.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

Authors:  F Jamen; K Persson; G Bertrand; N Rodriguez-Henche; R Puech; J Bockaert; B Ahrén; P Brabet
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Adrenalectomy impairs vasoactive intestinal peptide-induced changes in food intake and plasma parameters.

Authors:  Marcela Cristina Garnica-Siqueira; Andressa Bussetti Martins; Larissa Rugila Dos Stopa; Camila Franciele de Souza; Dimas Augusto Morozin Zaia; Cristiane Mota Leite; Cássia Thaïs Bussamra Vieira Zaia; Ernane Torres Uchôa
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

Review 7.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 8.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

9.  Altered social behavior in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice.

Authors:  Arnaud Nicot; Timothy Otto; Philippe Brabet; Emanuel M Dicicco-Bloom
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

Review 10.  Role of PACAP in ischemic neural death.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.